Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is a single-site, randomized, placebo-controlled, double blind phase 2b clinical trial.
Patients with Thalassemia will participate in this study and will be treated with Denosumab
or placebo. The effect of Denosumab on lumbar spine BMD in patients with Thalassemia Major
and Osteoporosis will be evaluated as compared with control (placebo) at 12 months.